Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)

According to the recommendations of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Neurocognition Committee, one of the desired characteristics of a cognitive battery for assessing cognition in schizophrenia studies and clinical trials is the availability of normative data. This report describes normative data collected on the Brief Assessment of Cognition in Schizophrenia (BACS) from 404 healthy controls with demographic characteristics matching the 2005 United States Census of English-speakers. The six test measures demonstrated the expected pattern of correlations with age, gender, and education. Individual test scores were converted into standardized (T and z) scores and composite scores that were corrected for age and gender. An education-correction factor was calculated and recommended only for non-schizophrenia patients. Eight different verbal memory tests were found to have equivalent levels of difficulty.     

精神分裂症认知功能简明成套测评量表（中文版,BACS）信度、效度研究

目的对精神分裂症认知功能简明成套测评量表（中文版,BACS）的信度、效度进行测试。方法选取56例符合CCMD-3诊断标准的新近住院精神分裂症和分裂样精神障碍患者进行精神分裂症认知功能简明成套测评量表（中文版,BACS）评测,并对所获资料进行因子分析和信度分析法。结果①因子分析法显示KMO统计量为0.820,Bartlett球形检验,χ^2=102.430,P〈0.01,主成分分析可将其分为3因子。②各个分测验评分之间的相关系数在0.126～0.582之间,除了伦敦塔和语义流畅性之外,其他均具有显著相关性。③标准化Cronbach α=0.81。④A、B版本亚表之间的相关性在0.736～0.968之间,均具有显著性。结论精神分裂症认知功能简明成套测评量表（中文版,BACS）具有较好的信度、效度,是一种较好的精神分裂症认知功能评测工具,适合汉语地区临床应用。     

Validation of the German Version of the Brief Assessment of Cognition in Schizophrenia (BACS) - Preliminary Results

The German version of the BACS showed high test-retest reliability. Sensitivity and specificity scores demonstrated good ability to differentiate between patients and controls. The study suggests that the German Version of the BACS is a useful scale to evaluate cognitive functioning.     

Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls

Neurocognitive impairment is a core feature of schizophrenia and is closely associated with functional outcome. The importance of cognitive assessment is broadly accepted today, and an easy-to-use, internationality validated cognitive assessment tool is needed by researchers and in daily clinical practice. The Brief Assessment of Cognition in Schizophrenia (BACS) has been validated in English, French, Japanese and Italian. It is as sensitive to cognitive dysfunction as a standard test battery, with the advantage of requiring less than 35 minutes to complete. In our study, we tested the psychometric characteristics of a Spanish version of the BACS in 117 patients with schizophrenia-spectrum disorders and 36 healthy controls. All BACS cognitive subtests discriminated between patients and controls (P < .001), and the concurrent validity between the BACS and a traditional neuropsychological test battery was similar to that reported in other languages. We conclude that the BACS can facilitate the comparison of the cognitive performance of patients with schizophrenia in many different countries.     

The Brief Assessment of Cognition in Schizophrenia. Normative data for the Italian population

OBJECTIVE: To provide normative values for the Italian population for the Brief Assessment of Cognition in Schizophrenia (BACS), a recent brief neuropsychological instrument for the assessment of cognition in patients with schizophrenia. PARTICIPANTS: Data were collected from 204 healthy adult Italian subjects, stratified by gender, education and age. MEASUREMENTS AND RESULTS: Tests included in the BACS are the following: list learning, digit sequencing, verbal fluency, token motor task, symbol-coding and Tower of London. Normative values were established using the Equivalent Scores method in order to enable comparison with other neuropsychological tasks commonly used in the assessment of the Italian population. Performance on the BACS was influenced by the commonest demographic variables such as age and education. CONCLUSIONS: The availability of normative data for the Italian population will increase the usefulness of this test for both clinical and experimental purposes.     

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery

Studies of neurocognitive function in patients with schizophrenia use widely variable assessment techniques. Clinical trials assessing the cognitive enhancing effect of new medications have used neurocognitive assessment batteries that differed in content, length and administration procedures. The Brief Assessment of Cognition in Schizophrenia (BACS) is a newly developed instrument that assesses the aspects of cognition found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The BACS requires less than 35 min to complete in patients with schizophrenia, yields a high completion rate in these patients, and has high reliability. The BACS was found to be as sensitive to cognitive impairment in patients with schizophrenia as a standard battery of tests that required over 2 h to administer. Compared to healthy controls matched for age and parental education, patients with schizophrenia performed 1.49 standard deviations lower on a composite score calculated from the BACS and 1.61 standard deviations lower on a composite score calculated from the standard battery. The BACS composite scores were highly correlated with the standard battery composite scores in patients (r=0.76) and healthy controls (r=0.90). These psychometric properties make the BACS a promising tool for assessing cognition repeatedly in patients with schizophrenia, especially in clinical trials of cognitive enhancement.     

Brief report: relationship between self-awareness of real-world behavior and treatment outcome in autism spectrum disorders

The aim of the present study was to investigate the influence of self-awareness of real-world behavior on treatment outcome in adolescents with ASD. For this purpose we followed 28 adolescents with ASD during their first year of specialized treatment. Results showed that better self-awareness at start of treatment was related with an increase in clinician-reported social functioning after 1 year of treatment. Additionally, an increase in self-awareness during treatment was related with a decrease of parent-reported problems in daily functioning. However, an increase in self-awareness was also related to an increase of self-reported daily and psychological problems. It is discussed that lowered self-awareness may result in an overestimation of personal real-world functioning and consequently may influence treatment course.     

The Philadelphia Brief Assessment of Cognition (PBAC): a validated screening measure for dementia

The Philadelphia Brief Assessment of the Cognition (PBAC) is a brief dementia-screening instrument. The PBAC assesses five cognitive domains: working memory/executive control; lexical retrieval/language; visuospatial/visuoconstructional operations; verbal/visual episodic memory; and behavior/social comportment. A revised version of the PBAC was administered to 198 participants including patients with Alzheimer's disease (AD) (n=46) and four groups of patients with frontotemporal dementia (FTD) syndromes: behavioral-variant FTD (bvFTD; n=65), semantic-variant primary progressive aphasia (PPA) (svPPA; n=22), non-fluent/agrammatic-variant PPA (nfaPPA; n=23), and corticobasal syndrome (CBS; n=42), and a group of normal controls (n=15). The total PBAC score was highly correlated with the MMSE. The criterion validity of the PBAC was assessed relative to standard neuropsychological test performance. Using standard neuropsychological test performance as a criterion, the total PBAC score accurately identified the presence and severity of dementia. Intra-class correlations between PBAC subscales and standard neuropsychological tests were highly significant. PBAC subscales demonstrated good clinical utility in distinguishing AD and FTD subtypes using receiver operating characteristic analysis and standard diagnostic performance statistics to determine optimal subscale cut scores. The PBAC is a valid tool and able to assesses differential patterns neuropsychological/behavioral impairment in a broad range of neurodegenerative conditions.     

The Philadelphia Brief Assessment of Cognition (PBAC): A Validated Screening Measure for Dementia

The Philadelphia Brief Assessment of the Cognition (PBAC) is a brief dementia-screening instrument. The PBAC assesses five cognitive domains: working memory/executive control; lexical retrieval/language; visuospatial/visuoconstructional operations; verbal/visual episodic memory; and behavior/social comportment. A revised version of the PBAC was administered to 198 participants including patients with Alzheimer's disease (AD) (n?=?46) and four groups of patients with frontotemporal dementia (FTD) syndromes: behavioral-variant FTD (bvFTD; n?=?65), semantic-variant primary progressive aphasia (PPA) (svPPA; n?=?22), non-fluent/agrammatic-variant PPA (nfaPPA; n?=?23), and corticobasal syndrome (CBS; n?=?42), and a group of normal controls (n?=?15). The total PBAC score was highly correlated with the MMSE. The criterion validity of the PBAC was assessed relative to standard neuropsychological test performance. Using standard neuropsychological test performance as a criterion, the total PBAC score accurately identified the presence and severity of dementia. Intra-class correlations between PBAC subscales and standard neuropsychological tests were highly significant. PBAC subscales demonstrated good clinical utility in distinguishing AD and FTD subtypes using receiver operating characteristic analysis and standard diagnostic performance statistics to determine optimal subscale cut scores. The PBAC is a valid tool and able to assesses differential patterns neuropsychological/behavioral impairment in a broad range of neurodegenerative conditions.     

The Norwegian standardization of the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery

This is the first international reference study of neurocognitive function as assessed by the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB). Two hundred and fifty healthy Norwegian men and women between the ages of 12 and 59 years were tested. The results were broken down across gender, age, and education level. In the adult group, women performed better than men on Speed of Processing and Verbal Learning, and men outperformed women on Attention/Vigilance and Reasoning/Problem Solving tasks. There were substantial reductions in most domains of cognitive function with increasing age. The effect of education on cognitive performance was more modest. Although our results are somewhat divergent from the US normative study, we conclude that the MCCB is well suited for research purposes and clinical use in Norway.     

The relationship between cognition and functional outcome in schizophrenia

Schizophrenia is associated with poor functional outcome, which has been shown to be associated with cognitive impairment, a core feature of the illness. The aim of the present study is to provide an overview of measurements of cognitive deficit and everyday functioning in schizophrenia. The authors demonstrate that cognitive impairment is a predictor of subsequent functional outcome measures by reviewing the relevant cross-sectional and longitudinal studies. Furthermore, models proposing intermediate variables that may provide a link between cognition and functional outcome are discussed. Such mediator variables are social cognition and functional capacity. Future avenues of research on cognition and functional outcome in schizophrenia are outlined, as there is considerable interest in finding treatments to improve cognition in schizophrenia. Improvements in cognitive deficits are expected to lead to benefits in the everyday functioning of the patients.     

Establishing the Brief Assessment of Cognition - Short form

The study aims to identify and validate a parsimonious subset of tests in the commonly used Brief Assessment of Cognition in Schizophrenia (BACS) that allows the evaluation of global cognitive ability. Several permutations of subtests from the BACS were examined to identify the best subset of tests to compose the short form measure. The Brief Assessment of Cognition-Short Form (BAC-SF) was evaluated for convergent validity in healthy and psychiatric samples (N = 3718). Verbal Memory, Digit Sequencing, and Symbol Coding subtests were found to best summarize the variance of composite scores in both Asian and US Norming samples (r = 0.91) indicating that BAC-SF is an appropriate approximation of cognitive deficits. Test re-test reliability of the BAC-SF was adequate (Intraclass Correlation Coefficient (ICC) = 0.73) and showed sufficient separation between healthy controls and schizophrenia (Average Predictive Accuracy = 79.9%; replication = 76.5%). Findings indicate that the BAC-SF an could be used as a cognitive screener for large-scale clinical and epidemiological studies. The short form does not replace the need for comprehensive neuropsychological batteries purposed for detailed neuropsychological and clinical investigation of cognitive function. Further replication of the construct might be necessary in other clinical populations.     

Brief psychotherapy of bereavement reactions. The relationship of process to outcome

We studied the relationship of dispositional and process variables with outcome in 52 bereaved patients given time-limited dynamic psychotherapy. Outcomes were generally favorable in symptom relief and improvement in relationship and occupational functioning. Patients' symptoms improved more than did their social and work functioning. Pretreatment levels of impairment or distress were significantly related to outcome, but most demographic and dispositional variables did not predict outcome. Process variables examined in relation to outcome--therapeutic alliance and actions by the therapist--were not significantly related to either type of outcome. When we considered the same process variables in interaction with two dispositional variables, motivation for dynamic therapy and developmental level of the self-concept, we found significant predictions of outcome. The major findings suggest that more exploratory actions were more suitable for highly motivated and/or better-organized patients and less suitable for patients with lower levels of motivation or organization of self-concept. More supportive actions were more suitable for patients at lower dispositional levels and less therapeutic for patients at higher levels.     

Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A)

BackgroundAlthough cognitive impairment is a core feature of bipolar disorder (BD) there is no instrument of choice for the assessment of bipolar patients. The aim of this study is to assess cognitive performance using the Brief Assessment of Cognition in Affective Disorders (BAC-A), a comprehensive test battery developed specifically for BD, and determine its suitability to estimate global functioning.MethodsThe BAC-A was administered to 93 BD patients (M ± S.E: 35.18 ± 1.39 years) and 56 healthy controls (HC – M ± S.E: 36.17 ± 1.91 years). The scores of the BAC-A were combined in eight summary scores: visuomotor, immediate affective and non-affective memory, verbal fluency, delayed affective and non-affective memory, inhibition, and problem solving. Post hoc analyses were performed on subtests of the summary scores found to be significantly different between BD patients and HC. Correlational analyses explored the association between the Global Assessment of Functioning (GAF) score and cognitive functioning.ResultsCompared to HC, BD patients showed a significant impairment in short-term non-affective memory and verbal fluency. Poorer performance in verbal memory and verbal fluency summary scores correlated positively with reduced GAF.ConclusionsOur results are consistent with previous reports of verbal memory and verbal fluency impairment in BD. The deficits in short-term memory and semantic fluency may indicate inefficient learning strategies and/or difficulties in retrieving information. The BAC-A could be used to estimate global functioning in BD patients.     

Philadelphia Brief Assessment of Cognition in healthy and clinical Brazilian sample

The Philadelphia Brief Assessment of Cognition (PBAC) is a neuropsychological screening instrument that assesses five cognitive domains: working memory, visuospatial functioning, language, episodic memory and comportment. The aim is to verify if PBAC can properly be used in the Brazilian sample. Participated in this study: (a) 200 healthy volunteers - 100 young [21.6(2.5) years old] and 100 older adults [70.1(7.3) years old]; >12 years of education; (b) 30 Alzheimer's patients (AD) [73.7(5.7) years old], 4-11 years in education. The PBAC scores: (a) 95.8(2.6), 90.0(4.4) and (b) 65.0(10.8) were correlated with the Mini-Mental State Examination (MMSE) for young 29.1(0.9), older adults 28.3(1.4) and AD 18.4(3.0) groups. A positive correlation between MMSE and PBAC (r=0.9, p<0.001) was found. Negative correlations were observed between PBAC domains [memory (-0.63), visuospatial abilities (-0.44) and working memory (-0.3) tasks]. MANOVA showed a better male performance in visuospatial functioning (F=8.5, p=0.004). The Brazilian version of PBAC proved to be a promising screening instrument for clinical purposes.     

Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms

OBJECTIVE: Impairments in adaptive life skills are a major source of disability in patients with schizophrenia. The relationship between adaptive life skills in real-world settings and performance on neuropsychological tests may be complicated by other factors that interfere with deployment of skills. Assessment of the ability to perform life skills under optimal conditions (i.e., assessment of functional capacity) has been proposed as a means to clarify these relationships. METHOD: The authors examined cross-sectional data from a study of the course of neuropsychological and adaptive life skills of older (age 50-85) schizophrenia patients (N=78). Functional capacity was examined with a performance-based measure (UCSD Performance-Based Skills Assessment), and case managers rated real-world adaptive functions (i.e., interpersonal skills, work skills, and community activities). Neuropsychological performance was assessed with a comprehensive battery, while symptoms were assessed with patient self-report and clinical ratings. RESULTS: Confirmatory path analyses were used to evaluate the effects of neuropsychological performance, functional capacity, and symptoms on the various domains of real-world functioning. Neuropsychological performance predicted functional capacity, which predicted all three domains of real-world functioning. Depression predicted interpersonal and work skills, while negative symptoms affected interpersonal skills independently of other predictors. CONCLUSIONS: Real-world adaptive life skills are predicted by neuropsychological performance, symptoms, and functional capacity. Neuropsychological performance contributes little to the prediction of real-world performance after accounting for functional capacity. In some domains, negative and depressive symptoms influenced real-world performance while not relating to functional capacity or neuropsychological performance.